Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Brief Summary: Primary Objective:

To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.

Secondary Objectives:

* To evaluate the safety and tolerability of dupilumab.
* To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.
* To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Intervention Type: DRUG; Name: Anti-IgE antibody omalizumab or placebo; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo (for Dupilumab 200 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Placebo (for Dupilumab 300 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Inhaled corticosteroid (ICS) therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Levalbuterol/Levosalbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Mometasone furoate 50 micrograms | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Mometasone furoate 50 micrograms | Intervention Type: DRUG; Name: Dupilumab SAR231893 (REGN668); Assigned to Arm(s): Dupilumab 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mometasone furoate 50 micrograms; Assigned to Arm(s): Dupilumab 300 mg, Placebo

Answer: C